Donate For Public and Patients Store Search

S034 - Late-breaking Research: Clinical Trials

Saturday, March 2; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Describe ground-breaking scientific developments in dermatologic research.
  • Evaluate and apply information from recent investigations to clinical practice.

Description

Researchers can submit abstracts describing their most recent unpublished results. After a competitive review, the top scoring studies will be invited to discuss their findings in a brief oral presentation during one of the themed sessions. This year, there will be three Forums (clinical/pediatric dermatology, surgery/procedural dermatology and basic science/dermatopathology) and a new Clinical Trials Symposium. Together, these sessions will highlight the latest ground-breaking observations in all aspects of dermatological research.

Disclosures

  • Baker, Diane Romayne, MD: Aimmune Therapeutics, Inc. – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Regeneron – I(Grants/Research Funding); sanofi-aventis – O(Grants/Research Funding);
  • Blauvelt, Andrew, MD: AbbVie – A(H), C(H), I(Fees), SP(H); Aclaris Therapeutics Inc. – A(H), C(H), I(Fees); Akros Pharma, Inc. – A(H), C(H); Allergan, Inc – A(H), C(H), I(Fees); Almirall – A(H), C(H); Amgen – A(H), C(H), I(Fees); Arena Pharmaceuticals – A(H), C(H); Athenex – A(H), C(H), I(Fees); Boehringer Ingelheim – A(H), C(H), I(Fees); Bristol-Myers Squibb – A(H), C(H); Celgene – A(H), C(H), I(Fees); Dermavant Sciences – A(H), C(H), I(Fees); Dermira – A(H), C(H), I(Fees); Eli Lilly and Company – A(H), C(H), I(Fees); FLX Bio – A(H), C(H); Forte Biosciences – A(H), C(H); Galderma Laboratories, L.P. – A(H), C(H); Galderma USA – I(Fees); Genentech, Inc. – A(H), C(H), I(Fees); GlaxoSmithKline – A(H), C(H), I(Fees); Janssen-Ortho Inc. – A(H), C(H), I(Fees), SP(H); Leo Pharma Inc – A(H), C(H), I(Fees); Meiji Seika Pharma Co., Ltd – A(H), C(H); Merck & Co., Inc – A(H), C(H), I(Fees); Novartis Pharmaceuticals Corp. – A(H), C(H), I(Fees); Pfizer Inc. – A(H), C(H), I(Fees); Purdue Pharma – A(H), C(H); Regeneron – A(H), C(H), I(Fees), SP(H); Revance Therapeutics, Inc. – I(Fees); Sandoz, a Novartis company – A(H), C(H), I(Fees); Sanofi – A(H), C(H), SP(H); Sienna Biopharmaceuticals – A(H), C(H), I(Fees); Sun Pharmaceutical Industries Ltd. – A(H), C(H); UCB – A(H), C(H), I(Fees); Valeant Pharmaceuticals International – A(H), C(H), I(Fees); Vidac Pharma – A(H), C(H), I(Fees);
  • Blume-Peytavi, Ulrike, MD: Almirall – A(H); Cassiopea S.p.A. – C(H); Johnson & Johnson Consumer Products Company – C(H); Leo Pharma A/S – C(H); Pfizer Inc. – A(H);
  • Cassella, James: Concert Pharmaceuticals – E(S), E(SO), E(ST);
  • Gelfand, Joel M., MD, MSCE: AbbVie – I(Grants/Research Funding); BMS – C(Fees); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); Eli Lilly and Company – O(Fees); GlaxoSmithKline – C(H); Janssen Pharmaceuticals, Inc – C(H), I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H), I(Grants/Research Funding); Ortho Dermatologics – I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); Sanofi US Services – C(H); Society for Investigative Dermatology – O(H); UCB – O(Fees);
  • Goldust Jouybari, Mohamad, MHS: no financial relationships exist with commercial interests.
  • Gordon, Kenneth B., MD: AbbVie – C(H), I(Grants/Research Funding); Almirall – C(H); Amgen – C(H), I(Grants/Research Funding); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Bristol-Myers Squibb – C(H); Celgene Corporation – A(H), I(Grants/Research Funding); Demira – C(H); Dermavant Sciences – C(H); Eli Lilly and Company – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(H), I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – C(H); Leo Pharma Inc – C(H); Lilly ICOS LLC – A(H); Novartis – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H); Othro Dermatologics – C(H); Pfizer Inc. – A(H); Sun Pharmaceutical Industries Ltd. – C(H); UCB – C(H);
  • Gottlieb, Alice B., MD, PhD: AbbVie – C(H), SP(H); amgen – A(H); Avotres, Inc. – C(NC); BMS – A(H); Boehringer Ingelheim – I(Grants/Research Funding); Celgene Corporation – A(H); Dermira – C(H); Eli Lilly and Company – SP(H); Incyte Corporation – C(H), I(Grants/Research Funding); Janssen Biotech – A(H), SP(H); Janssen-Ortho Inc. – A(H), I(Grants/Research Funding); LEO Pharma, US – A(H); Lilly ICOS LLC – C(H); Novartis – A(H), C(H), I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – C(H); UCB – A(H), I(Grants/Research Funding); XBiotech – C(NC), I(Grants/Research Funding);
  • Hebert, Adelaide A., MD: Allergan, Inc. – I(Grants/Research Funding); Almirall – A(H); Amgen – I(Grants/Research Funding), SP(H); Anacor Pharmaceuticals, Inc. – A(H); Astellas Pharma US, Inc – I(Grants/Research Funding); Bayer – SP(H); Bickel Biotechnology – I(Grants/Research Funding); Biofrontera – SP(H); Cassiopia – I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); Chugai Pharma – I(Grants/Research Funding); Cutanea Life Sciences – A(H), I(Grants/Research Funding); Department of DEFENSE – O(Grants/Research Funding); Dermavant Sciences – A(H), I(Grants/Research Funding); Dermira – A(H), I(Grants/Research Funding); Encore Dermatology, Inc. – A(H); Fall Clinical Dermatology Conference – SP(H); Ferrer – C(H); Galderma Laboratories, L.P. – A(H), SP(H); GlaxoSmithKline – A(H), Data Safety Monitoring Board(H), I(Grants/Research Funding); Healthpoint – I(Grants/Research Funding); Intendis, Inc. – SP(H); La Roche-Posay Laboratoire Pharmaceutique – A(H); Mayne Pharma Group – I(Grants/Research Funding); Medimetriks Pharmaceuticals, Inc. – I(Grants/Research Funding); Menarini Group – SP(H); Menlo Therapeutics – A(H); Merz Pharmaceuticals, LLC – I(Grants/Research Funding); NIH – I(Grants/Research Funding); Novan – I(H); Novartis Pharmaceuticals Corp. – O(H); Onset Therapeutics – SP(H); Ortho Dermatologics – A(H); Pfizer Inc. – I(Grants/Research Funding), Speaker/Faculty Education(H); Pharmaderm – A(H); PPD Inc. – I(Grants/Research Funding); Prim-Med – SP(H); Promius Pharma, LLC – A(H); Promius Pharmaceuticals – A(H), I(Grants/Research Funding); Regeneron – Data Safety Monitoring Board(H); Roivant Sciences – A(H); Shionogi USA – A(IP); Sienna Biopharmaceuticals – I(Grants/Research Funding); Sinclair Pharma – SP(H); Spring Managed Care Forum – SP(H); Stiefel a GSK company – A(H); TopMD – I(Grants/Research Funding); Valeant Pharmaceuticals International – A(H), SP(H); Vanda Pharmaceuticals Inc. – I(Grants/Research Funding); Verrica Pharmaceuticals Inc – A(Fees);
  • Lain, Edward L., MD: AbbVie – I(Grants/Research Funding); Aclaris Therapeutics Inc. – I(Grants/Research Funding), SP(H); Allergan, Inc – A(H), I(Grants/Research Funding), Speaker/Faculty Education(Fees); Almirall – A(H), C(H), SP(H); AstraZeneca – I(Grants/Research Funding); Athenix – I(Grants/Research Funding); Biopelle, Inc. – C(H); BioPharmX – I(Grants/Research Funding); Biorasi, LLC – I(Grants/Research Funding); BMS – I(Grants/Research Funding); Brickell Biotech, Inc. – I(Grants/Research Funding); Cassiopea S.p.A. – I(Grants/Research Funding); Celgene – I(Grants/Research Funding); Cellceutix – I(Grants/Research Funding); ChemoCentryx – I(Grants/Research Funding); Cutanea Life Sciences – I(Grants/Research Funding); Demira – C(H); Dermira – A(H), I(Grants/Research Funding); Dow Pharmaceutical Sciences, Inc. – I(Grants/Research Funding); Dr Reddy's Laboratory – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Gage Development Company, LLC – I(Grants/Research Funding); Galderma Laboratories, L.P. – I(Grants/Research Funding), SP(H); Galderma USA – A(H), I(Grants/Research Funding); Hovione – I(Grants/Research Funding); Kadmon Corporation, LLC – I(Grants/Research Funding); La Roche-Posay Laboratorie Pharmaceutique – SP(H); LEO Laboratories Ltd (LEO Pharma) – I(Grants/Research Funding); Medimmune – I(Grants/Research Funding); Menlo Therapeutics – A(H), I(Grants/Research Funding); Moleculin LLC – SH(ST); Neothetics – I(Grants/Research Funding); Nielsen Holdings N.V – I(Grants/Research Funding); Novartis – A(H), I(Grants/Research Funding); Othro Dermatologics – A(H), I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding), SP(H); Promius Pharma, LLC – SP(H); Sebacia, Inc. – I(Grants/Research Funding); Sienna Labs, Inc. – I(Grants/Research Funding); SkinCeuticals LLC – A(H), SP(H); Sol-Gel Technologies – I(Grants/Research Funding); UCB – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding);
  • Langley, Richard G. B., MD: AbbVie – A(H), I(Grants/Research Funding), SP(H); Amgen – I(Grants/Research Funding), SP(H); Astellas Pharma US, Inc – I(Grants/Research Funding); Boehringer Ingelheim – A(H), I(Grants/Research Funding); Celgene Corporation – A(H); Centocor Ortho Biotech Inc. – A(H), I(Grants/Research Funding); Eli Lilly and Company – A(H), I(H); Genentech, Inc. – I(Grants/Research Funding); Isotechnika Pharma Inc. – I(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – I(Grants/Research Funding); Merck Serono – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H), I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding), SP(H);
  • Murrell, Dedee F., MD: 3M Pharmaceuticals – C(Grants/Research Funding); Abbott Laboratories – A(H), SP(H); AbbVie – I(Grants/Research Funding); Actavis – Speaker/Faculty Education(H); Almirall – C(H); Amgen – I(Fees); Amicus Therapeutics – A(H); Anacor Pharmaceuticals, Inc. – I(Grants/Research Funding); Ascent Pharmaceuticals – SP(H); Castle Creek Pharmaceuticals – C(Fees); CSL – SP(Grants/Research Funding), SP(H); Delfin Technology – I(EQ); Eli Lilly and Company – A(H); Galderma Laboratories, L.P. – I(Grants/Research Funding), I(OB); Janssen-Ortho Inc. – O(Grants/Research Funding); Leo Pharma Inc – Speaker/Faculty Education(H); Medimmune – I(Grants/Research Funding); Merck Serono – I(Fees), I(Grants/Research Funding); Molynlycke – SP(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H), I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Pierre Fabre Dermo-Cosmétique US – SP(H); Principia Biopharma Inc – C(H); Roche Laboratories – A(H), I(Grants/Research Funding); Samumed, LLC – I(Grants/Research Funding); Schering-Plough Corporation – I(Grants/Research Funding), SP(OB); Shire – A(H), I(Grants/Research Funding); Stiefel a GSK company – SP(H); XOMA (US) LLC – I(Grants/Research Funding);
  • Peeva, Elena: Pfizer Inc. – E(S);
  • Simpson, Eric Lawrence, MD: AbbVie – C(Fees), I(Grants/Research Funding); Boehringer Ingelheim – C(Fees); Demira – C(Fees); Dermavant Sciences – C(Fees); Eli Lilly and Company – C(Fees), I(Grants/Research Funding); Forte Biosciences – C(Fees); Galderma Laboratories, LP – I(Grants/Research Funding); Incyte Corporation – C(Fees); Kyowa Hakko Kirin Pharma, Inc. – I(Grants/Research Funding); Leo Pharma Inc. – C(Fees), I(Grants/Research Funding); Menlo Therapeutics Inc. – C(Fees); Merck – I(Grants/Research Funding); Pfizer Inc. – C(Fees), I(Grants/Research Funding); Pierre Fabre Dermo Cosmetique France – C(Fees); Regeneron – C(Fees), I(Grants/Research Funding); Sanofi Genzyme – C(Fees); Valeant Pharmaceuticals International – C(Fees);
  • Smith, Stacy R., MD: AbbVie – I(Grants/Research Funding), SP(H); Aclaris Therapeutics Inc. – I(Grants/Research Funding); Aclaris Therapeutics, Inc. – C(Fees); AmperSand Biopharmaceutical, LLC – I(Grants/Research Funding); Boehringer Ingelheim – I(Grants/Research Funding); Brickell Biotech, Inc. – I(Grants/Research Funding); Croma-Pharma GmbH Austria – I(Grants/Research Funding); Dermira – I(Grants/Research Funding); Endo International plc – I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H), I(Grants/Research Funding); Galderma Research & Development, LLC – C(Fees); Glenmark Generics Inc. – I(Grants/Research Funding); Illumicare – I(Grants/Research Funding); Leo Pharma Inc – I(Grants/Research Funding); Lilly ICOS LLC – A(H), I(Grants/Research Funding), SP(H); Menlo Therapeutics – I(Grants/Research Funding); Nielsen Bioscience, Inc. – C(Fees); Novartis Pharmaceuticals Corp. – A(H), I(Grants/Research Funding); Otsuka Pharmaceutical Co., Ltd. – Data Safety Monitoring Board(Fees); Pfizer Inc. – I(Grants/Research Funding); Prollenium Medical Technologies – I(Grants/Research Funding); Revance Therapeutics, Inc. – I(Grants/Research Funding); Scarless Labs – C(Fees); Suneva Medical, Inc. – C(Fees); TEOXANE Laboratories – C(Fees);
  • Spellman, Mary C., MD: Menlo Therapeutics – E(S);
  • Tsao, Hensin, MD, PhD: Asana Biosciences, LLC – I(Grants/Research Funding); Epiphany Dermatology – A(H); Massachusetts General Hospital – E(S); Relay Therapeutics – I(Grants/Research Funding); UpToDate, Inc. – O(H); Worldcare Clinical, LLC – C(H);
  • Wollenberg, Andreas, MD: Almirall – C(Fees); Eli Lilly and Company – I(Fees), SP(H); Galderma Germany – A(H); Galderma Global – A(H), I(Fees); L'Oreal Deutschland GmbH – SP(H); Leo Pharma A/S – A(H), I(Fees), SP(H); Novartis – A(H), Speaker/Faculty Education(H); Pfizer Inc. – A(H), I(H), SP(H); Pierre Fabre Dermo Cosmetique France – SP(H); Sanofi Genzyme – SP(H); Sanofi/Regeneron – A(H), I(H); Santen Pharmaceutical Co., Ltd. – A(H);
Schedule
Saturday, March 2
1:00 PM
Dr. Langley / Secukinumab Maintains Improvements in Psoriasis through Five Years of Treatment: A randomized extension of the phase III ERASURE and FIXTURE Trials
1:10 PM
Dr. Simpson / Bermekimab is a Rapid and Effective Treatment for Atopic Dermatitis (AD)
1:20 PM
Cassella / JAK Inhibitor CTP-543 Achieves Primary Endpoint in Phase 2 Trial in Alopecia Areata
1:30 PM
Peeva / Oral Janus Kinase Inhibitors PF-06700841 and PF-06651600 Provide Clinically Evident Therapeutic Effect at 4 and 6 Weeks in Patients with Alopecia Areata and Greater Efficacy over 24 Weeks in Patients
1:40 PM
Dr. Blume-Peytavi / Clascoterone Topical Solution, an Investigational, Selective Androgen Receptor Antagonist: Results from a pivotal phase II dose ranging study in men with androgenetic alopecia (AGA)
1:50 PM
Dr. Gottlieb / Bermekimab Shows Efficacy for Treating Hidradenitis Suppurativa (HS) Including Marked Reduction in Pain
2:00 PM
Dr. Baker / Ligelizumab Achieves Sustained Symptom Control up to 1 Year in the Majority of Patients with Chronic Spontaneous Urticaria
2:10 PM
Dr. Murrell / Final Results of the Believe-PV Proof of Concept Study of PRN1008 in Pemphigus
2:20 PM
Augustin / Secukinumab Treatment Results in Normalization of Quality of Life in Patients with Moderate to Severe Psoriasis with and without Previous Systemic Therapy: Results from the PROSE Study
2:30 PM
Goldust Jouybari / Efficacy and Safety of Adalimumab Plus Methotrexate Versus Methotrexate Monotherapuy in Patients with Moderate to Severe Plaque Type Psoriasis, a Randomized Clinical Trial Study
2:40 PM
Dr. Blauvelt / Dual Neutralization of Interleukin (IL) 17A and IL 17F with Bimekizumab in Moderate-to-severe Plaque Psoriasis: 60-week Results from a Randomized, Double-blinded, Phase 2b Extension Study
2:50 PM
Dr. Gelfand / The VIP-S Trial: Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects with Moderate to Severe Plaque Psoriasis (NCT02690701)
3:00 PM
Dr. Wollenberg / Phase 2B Study OF Nemolizumab in Adults with Moderate-sever Atopic Dermatitis and Sever Prutitus
3:10 PM
Dr. Spellman / Serlopitant Reduced Pruritus Associated with Psoriasis in Phase 2 Randomized, Double-blind, Placebo-controlled Clinical Trial
3:20 PM
Goldust Jouybari / Oral Ivermectin vs. Oral Afoxolaner for theTreatment of Scabies a Prospective, Randomized, Double Blind, Controlled Study
3:30 PM
Dr. Smith / Successful Treatment of Common Warts with Candida Extract - A Phase II study
3:40 PM
Dr. Lain / KX2-391 Ointment 1%, a Novel Dual Src/Tubulin Inhibitor, is Efficacious and Safe in the Treatment of Adults with Actinic Keratosis in Two Phase III Studies
3:50 PM
Dr. Hebert / Clascoterone Topical Cream, 1%: A Novel, Topical, Local, Selective Androgen Receptor Antagonist: Results from Two Phase 3 Studies Treating Children and Adult Patients with Facial Acne Vulgaris
Event Details
  • Date
    Saturday, March 2
  • Time
    1:00 PM - 4:00 PM
  • Location
    Ballroom A
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
Speakers
  • Adelaide A. Hebert, MD, FAAD
  • Alice B. Gottlieb, MD, PhD, FAAD
  • Andreas Wollenberg, MD
  • Andrew Blauvelt, MD, FAAD
  • Dedee F. Murrell, MD, FAAD
  • Diane Romayne Baker, MD, FAAD
  • Edward L. Lain, MD, FAAD
  • Elena Peeva - Handout
  • Eric Lawrence Simpson, MD, FAAD
  • James Cassella
  • Joel M. Gelfand, MD, MSCE, FAAD
  • Kenneth B. Gordon, MD, FAAD
  • Mary C. Spellman, MD, FAAD
  • Matthias Augustin
  • Mohamad Goldust Jouybari, MHS
  • Richard G. B. Langley, MD, FAAD
  • Stacy R. Smith, MD, FAAD
  • Ulrike Blume-Peytavi, MD